Ignite Creation Date:
2025-12-25 @ 1:22 AM
Ignite Modification Date:
2026-01-29 @ 8:55 AM
Study NCT ID:
NCT03123393
Status:
TERMINATED
Last Update Posted:
2023-02-08
First Post:
2017-04-17
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Sponsor:
Calithera Biosciences, Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-10-10
Start Date Type:
ACTUAL
Primary Completion Date:
2019-12-17
Primary Completion Date Type:
ACTUAL
Completion Date:
2019-12-17
Completion Date Type:
ACTUAL
First Submit Date:
2017-04-17
First Submit QC Date:
None
Study First Post Date:
2017-04-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2020-08-06
Results First Submit QC Date:
None
Results First Post Date:
2020-09-16
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-02-06
Last Update Post Date:
2023-02-08
Last Update Post Date Type:
ACTUAL